Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 2/20 | 0.49 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20481003 | 0.92 | ITGAV (0.48) | ITGAVITGB6NPC1RAB9ATRPV3 | |
| SCHEMBL7403635 | 0.83 | ITGAV (0.58) | ITGAVITGB6NPC1RAB9A | |
| SCHEMBL2383101 | 0.83 | ITGAV (0.44) | ITGAVITGB6 | |
| SCHEMBL21317501 | 0.82 | ITGAV (0.67) | ITGAVITGB6 | |
| SCHEMBL21317498 | 0.81 | ITGAV (0.47) | ITGAVITGB6NPC1RAB9AGPR119 | |
| SCHEMBL20481052 | 0.80 | ITGAV (0.40) | ITGAVITGB6NPC1RAB9A | |
| SCHEMBL16668549 | 0.78 | ITGAV (0.43) | ITGAVITGB6NPC1RAB9AGPR119 | |
| SCHEMBL21317592 | 0.78 | ITGAV (0.43) | ITGAVITGB6NPC1RAB9AGPR119 | |
| SCHEMBL19384515 | 0.77 | ITGAV (0.65) | ITGAVITGB6 | |
| SCHEMBL17640900 | 0.77 | ITGAV (0.65) | ITGAVITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4159727-B1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12415796-B2 | Inhibitors of (αv)(β6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20240327378-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2024-10-03 | — | — | US | disclosed |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| CN-116283977-A | Inhibitors of αvβ6 integrin | 莫菲克医疗股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-110573499-B | Inhibitors of αvβ6 integrin | 莫菲克医疗股份有限公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-4159727-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | Morphic Therapeutic, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20210276975-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2021-09-09 | — | — | US | disclosed |
| US-20210276975-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2021-09-09 | — | — | US | disclosed |
| US-20040198718-A1 | Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2004-10-07 | — | — | US | disclosed |
| US-6743800-B1 | VITRONECTIN RECEPTOR ANTAGONISTS AND INHIBITORS OF CELL ADHESION; OSTEOPOROSIS, ANGIOGENESIS INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-01 | — | — | US | disclosed |
| US-20030171368-A1 | Pyrimidinonesulfamoylureas` | SEITZ WERNER (DE) | 2003-09-11 | — | — | US | disclosed |
| WO-2003066624-A1 | PYRIMIDINONESULFAMOYLUREAS AS INTEGRIN LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2003-08-14 | — | — | WO | disclosed |
| EP-0946165-B1 | INTEGRIN ANTAGONISTS | MERCK & CO INC (US) | 2003-04-09 | — | — | EP | disclosed |
| EP-1210348-A1 | NAPHTHYRIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Aventis Pharma Deutschland GmbH (DE) | 2002-06-05 | — | — | EP | disclosed |
| US-6358970-B1 | FOR THERAPY AND PROPHYLAXIS OF OSTEOPOROSIS, AND INHIBITING VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION, ARTHRITIS, VIRAL DISEASE, CANCER, AND METASTATIC TUMOR GROWTH | MERCK & CO., INC. | 2002-03-19 | — | — | US | disclosed |
| WO-2001002398-A1 | NAPHTHYRIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-01-11 | — | — | WO | disclosed |
| EP-1065207-A1 | Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them | Aventis Pharma Deutschland GmbH (DE) | 2001-01-03 | — | — | EP | disclosed |
| US-5952341-A | VITRONECTIN RECEPTOR ANTAGONISTS FOR INHIBITING BONE RESORPTION, TREATING AND PREVENTING OSTEOPOROSIS, AND INHIBITING RESTENOSIS, DIABETIC RETINOPATHY, TUMOR, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION | MERCK & CO., INC. (US) | 1999-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327378-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | ITGAV 3/4885ITGB6 1/4885NPC1 1992/4885 |
| US-20030171368-A1 | Pyrimidinonesulfamoylureas` | ITGB1, ITGA1, ITGAM | ITGAV 15/4885ITGB6 10/4885NPC1 3460/4885 |
| US-20210276975-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | ITGAV 3/4885ITGB6 1/4885NPC1 1992/4885 |
| US-12415796-B2 | Inhibitors of (αv)(β6) integrin | ITGB6, ITGA6, ITGAV | ITGAV 3/4885ITGB6 1/4885NPC1 1873/4885 |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | ITGAV 3/4885ITGB6 1/4885NPC1 1874/4885 |
| US-20040198718-A1 | Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them | VCAM1, ADGRF1, ADGRE5 | ITGAV 181/4885ITGB6 55/4885NPC1 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.